# Intchains Group Ltd: overview ICG · Nasdaq · CIK 1895597 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/icg.md) · [Financials](/companies/icg/financials.md) · [Filings](/companies/icg/filings.md) · [Insiders](/companies/icg/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters Not reported. ## Last five fiscal years | Line item | Unit | FY (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | [68.7](/filings/0001193125-23-123984.md) | [11.6](/filings/0001193125-24-070138.md) | [38.6](/filings/0001193125-25-105589.md) | [31.6](/filings/0001493152-26-016360.md) | | Gross margin | % | not reported | [81.6%](/filings/0001193125-23-123984.md) | [11.0%](/filings/0001193125-24-070138.md) | [53.7%](/filings/0001193125-25-105589.md) | [7.2%](/filings/0001493152-26-016360.md) | | Operating margin | % | not reported | [68.1%](/filings/0001193125-23-123984.md) | [(79.0%)](/filings/0001193125-24-070138.md) | [1.0%](/filings/0001193125-25-105589.md) | [(47.4%)](/filings/0001493152-26-016360.md) | | Net margin | % | not reported | [75.0%](/filings/0001193125-23-123984.md) | [(32.6%)](/filings/0001193125-24-070138.md) | [18.3%](/filings/0001193125-25-105589.md) | [(21.5%)](/filings/0001493152-26-016360.md) | | Diluted EPS | $ per share | [4.46](/filings/0001193125-24-070138.md) | [0.44](/filings/0001193125-23-123984.md) | [(0.03)](/filings/0001193125-24-070138.md) | [0.06](/filings/0001193125-25-105589.md) | [(0.06)](/filings/0001493152-26-016360.md) | | Free cash flow | $m | not reported | [46.8](/filings/0001193125-23-123984.md) | [(7.3)](/filings/0001193125-24-070138.md) | [(20.3)](/filings/0001193125-25-105589.md) | [(14.0)](/filings/0001493152-26-016360.md) | - Revenue. XBRL Revenue: us-gaap:Revenues. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:Revenues. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/icg/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Marex Group Ltd](/funds/1997464.md) | 2026-06-30 | $36.7k | 58,251 | | Added +43,129 | | [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $15.3k | 24,257 | | Reduced −36,306 | | [SmartHarvest Portfolios, LLC](/funds/2066604.md) | 2026-06-30 | $14.3k | 22,730 | | Reduced −29,572 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $1.5k | 2,359 | | Added +1,909 | | [MORGAN STANLEY](/funds/895421.md) | 2026-06-30 | $1.0k | 1,629 | | Unchanged | | [RHUMBLINE ADVISERS](/funds/1115418.md) | 2026-06-30 | $397 | 632 | | Added +605 | | [JPMORGAN CHASE & CO](/funds/19617.md) | 2026-06-30 | $50 | 75 | | Reduced −85 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $1 | 2 | | Unchanged | ## Recent filings [All 106 filings](/companies/icg/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-18 | 16:30 ET | [6-K](/filings/0001493152-26-043360.md) | Report of a foreign private issuer, period 2026-06-30 | 0001493152-26-043360 | | 2026-09-01 | 16:30 ET | [6-K](/filings/0001493152-26-041024.md) | Report of a foreign private issuer, period 2026-09-01 | 0001493152-26-041024 | | 2026-08-20 | 16:15 ET | [6-K](/filings/0001493152-26-039480.md) | Report of a foreign private issuer, period 2026-08-20 | 0001493152-26-039480 | | 2026-05-06 | 07:30 ET | [6-K](/filings/0001493152-26-021401.md) | Report of a foreign private issuer, period 2026-05-06 | 0001493152-26-021401 | | 2026-04-17 | 08:01 ET | [6-K](/filings/0001493152-26-017164.md) | Report of a foreign private issuer, period 2026-04-17 | 0001493152-26-017164 | | 2026-04-13 | 16:02 ET | [20-F](/filings/0001493152-26-016360.md) | Annual report of a foreign private issuer, period 2025-12-31 | 0001493152-26-016360 | | 2026-02-26 | 17:00 ET | [6-K](/filings/0001493152-26-008189.md) | Report of a foreign private issuer, period 2026-02-26 | 0001493152-26-008189 | | 2026-01-06 | 16:01 ET | [6-K](/filings/0001193125-26-004376.md) | Report of a foreign private issuer, period 2026-01-06 | 0001193125-26-004376 | | 2025-11-13 | 16:02 ET | [6-K](/filings/0001193125-25-280103.md) | Report of a foreign private issuer, period 2025-11-13 | 0001193125-25-280103 | | 2025-11-13 | 06:09 ET | [6-K](/filings/0001193125-25-278709.md) | Report of a foreign private issuer, period 2025-11-13 | 0001193125-25-278709 | ## Latest annual report [Form 20-F for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-016360.md), filed Apr 13, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1895597 - Tickers: ICG - Exchange: Nasdaq - SIC code: 3674 Semiconductors & Related Devices - State of incorporation: E9 - Filer category: Non-accelerated filer
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.